These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 23902712)
21. Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. Xu T; Wang NS; Fu LL; Ye CY; Yu SQ; Mei CL Mol Biol Rep; 2012 Jul; 39(7):7743-53. PubMed ID: 22415852 [TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease. Ibrahim NH; Gregoire M; Devassy JG; Wu Y; Yoshihara D; Yamaguchi T; Nagao S; Aukema HM Prostaglandins Other Lipid Mediat; 2015; 116-117():19-25. PubMed ID: 25447343 [TBL] [Abstract][Full Text] [Related]
23. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease. Wahl PR; Le Hir M; Vogetseder A; Arcaro A; Starke A; Waeckerle-Men Y; Serra AL; Wuthrich RP Nephrology (Carlton); 2007 Aug; 12(4):357-63. PubMed ID: 17635750 [TBL] [Abstract][Full Text] [Related]
24. Polycystic kidney disease in Han:SPRD Cy rats is associated with elevated expression and mislocalization of SamCystin. Nagao S; Morita M; Kugita M; Yoshihara D; Yamaguchi T; Kurahashi H; Calvet JP; Wallace DP Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1078-86. PubMed ID: 20719982 [TBL] [Abstract][Full Text] [Related]
25. ETA receptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease. Hocher B; Kalk P; Slowinski T; Godes M; Mach A; Herzfeld S; Wiesner D; Arck PC; Neumayer HH; Nafz B J Am Soc Nephrol; 2003 Feb; 14(2):367-76. PubMed ID: 12538737 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease. Riwanto M; Kapoor S; Rodriguez D; Edenhofer I; Segerer S; Wüthrich RP PLoS One; 2016; 11(1):e0146654. PubMed ID: 26752072 [TBL] [Abstract][Full Text] [Related]
27. Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease. Ecder T; Melnikov VY; Stanley M; Korular D; Lucia MS; Schrier RW; Edelstein CL Kidney Int; 2002 Apr; 61(4):1220-30. PubMed ID: 11918728 [TBL] [Abstract][Full Text] [Related]
28. The effect of paclitaxel on the progression of polycystic kidney disease in rodents. Martinez JR; Cowley BD; Gattone VH; Nagao S; Yamaguchi T; Kaneta S; Takahashi H; Grantham JJ Am J Kidney Dis; 1997 Mar; 29(3):435-44. PubMed ID: 9041221 [TBL] [Abstract][Full Text] [Related]
29. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED Kidney Int; 2003 Nov; 64(5):1573-9. PubMed ID: 14531789 [TBL] [Abstract][Full Text] [Related]
30. Methylprednisolone retards the progression of inherited polycystic kidney disease in rodents. Gattone VH; Cowley BD; Barash BD; Nagao S; Takahashi H; Yamaguchi T; Grantham JJ Am J Kidney Dis; 1995 Feb; 25(2):302-13. PubMed ID: 7847359 [TBL] [Abstract][Full Text] [Related]
31. The Endothelin system in polycystic kidneys of Han:SPRD rats. Hocher B; Zart R; Braun N; Schwarz A; van der Woude F; Rohmeiss P; Koppenhagen K J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S342-4. PubMed ID: 9595476 [TBL] [Abstract][Full Text] [Related]
32. Dietary conjugated linoleic acid renal benefits and possible toxicity vary with isomer, dose and gender in rat polycystic kidney disease. Ogborn MR; Nitschmann E; Goldberg A; Bankovic-Calic N; Weiler HA; Aukema HM Lipids; 2008 Sep; 43(9):783-91. PubMed ID: 18629561 [TBL] [Abstract][Full Text] [Related]
33. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. Tao Y; Kim J; Schrier RW; Edelstein CL J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559 [TBL] [Abstract][Full Text] [Related]
34. Renal cyclooxygenase and lipoxygenase products are altered in polycystic kidneys and by dietary soy protein and fish oil treatment in the Han:SPRD-Cy rat. Ibrahim NH; Jia Y; Devassy JG; Yamaguchi T; Aukema HM Mol Nutr Food Res; 2014 Apr; 58(4):768-81. PubMed ID: 24170691 [TBL] [Abstract][Full Text] [Related]
36. Global gene expression profiling in early-stage polycystic kidney disease in the Han:SPRD Cy rat identifies a role for RXR signaling. Kugita M; Nishii K; Morita M; Yoshihara D; Kowa-Sugiyama H; Yamada K; Yamaguchi T; Wallace DP; Calvet JP; Kurahashi H; Nagao S Am J Physiol Renal Physiol; 2011 Jan; 300(1):F177-88. PubMed ID: 20926632 [TBL] [Abstract][Full Text] [Related]
37. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. Belibi F; Ravichandran K; Zafar I; He Z; Edelstein CL Am J Physiol Renal Physiol; 2011 Jan; 300(1):F236-44. PubMed ID: 20943770 [TBL] [Abstract][Full Text] [Related]
38. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Dai B; Liu Y; Mei C; Fu L; Xiong X; Zhang Y; Shen X; Hua Z Clin Sci (Lond); 2010 Jul; 119(8):323-33. PubMed ID: 20507283 [TBL] [Abstract][Full Text] [Related]
39. Modification of polycystic kidney disease and fatty acid status by soy protein diet. Ogborn MR; Nitschmann E; Weiler HA; Bankovic-Calic N Kidney Int; 2000 Jan; 57(1):159-66. PubMed ID: 10620197 [TBL] [Abstract][Full Text] [Related]
40. Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease. Ramasubbu K; Gretz N; Bachmann S J Am Soc Nephrol; 1998 Jun; 9(6):937-45. PubMed ID: 9621276 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]